Last $13.69 USD
Change Today -0.06 / -0.44%
Volume 9.0M
BSX On Other Exchanges
New York
As of 8:04 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - $14.08
52 Week Low
04/25/13 - $7.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Natick, Massachusetts.

23,000 Employees
Last Reported Date: 02/26/14
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President of Global Operations...
Total Annual Compensation: $517.7K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Senior Advisor
Total Annual Compensation: $607.6K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Begins Clinical Trial of ACUITY(TM) X4 LV Pacing Leads and RELIANCE(TM) 4-FRONT ICD Leads

Boston Scientific Corporation has conducted the first implant in the clinical trial of the next generation ACUITY(TM) X4 left-ventricular (LV) pacing leads and RELIANCE(TM) 4-FRONT defibrillation (ICD) leads. The clinical trial is designed to establish the safety and effectiveness of both lead families and is intended to support U.S. Food and Drug Administration (FDA) approval of these devices. ACUITY X4 LV leads are quadripolar leads engineered to maximize effectiveness and minimize unnecessary patient interventions after implant. The unique three-dimensional spiral design is intended to minimize floating electrodes resulting in better electrical performance; in addition, dual-fixation zones and the 2.6 French crossing profile are designed to optimize lead stability and reduce the risk of dislodgement. When an ACUITY X4 lead is connected to a Boston Scientific X4 CRT-D, the resulting 17 pacing vector options are designed to improve physicians' ability to manage unexpected complications electronically through programming rather than an invasive lead revision. The RELIANCE 4-FRONT ICD lead is designed for reliability and performance over the long term. The lead maintains the same design principles as the industry's most reliable ICD lead, the ENDOTAK RELIANCE(TM) lead, yet offers improved handling and maneuverability. Additionally, the GORE(TM) coating securely adhered to the defibrillation coils is intended to prevent tissue in-growth and enable both a streamlined implant experience and easier extraction in case of infection. The NAVIGATE X4 trial is a prospective, non-randomized, multi-center, global clinical study designed to support FDA approval. The two principal investigators are Suneet Mittal, MD, director, Electrophysiology, Valley Health System and Martin C. Burke, DO, professor of medicine and director, Heart Rhythm Center, University of Chicago Medical Center. The trial is expected to enroll between 1,542 and 2,290 patients at up to 125 centers in the United States, Canada and Israel. The ACUITY X4 and RELIANCE 4-FRONT leads will be connected to commercially-available Boston Scientific X4 CRT-D devices. Leads are insulated wires that connect an implantable device to the heart for treatment of sudden cardiac arrest or heart failure. Cardiac Resynchronization Therapy Defibrillation (CRT-D) devices work in conjunction with leads to sense and stimulate (or pace) both right and left ventricles, thus resynchronizing the heart to provide appropriate function. Quadripolar CRT-D systems help physicians address high-pacing capture thresholds and phrenic nerve stimulation, a common complication of CRT therapy due to close proximity of the phrenic nerve to the desired pacing location in the left ventricle. The ACUITY X4 left ventricular pacing leads and RELIANCE 4-FRONT defibrillator leads are CE Marked. In the United States, they are investigational devices and not available for sale.

Boston Scientific Announces FDA Approval of New Defibrillators and Heart Failure Devices

Boston Scientific Corporation has received FDA approval for its generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN(TM) MINI and INOGEN(TM) MINI ICDs, as well as the DYNAGEN(TM) X4 and INOGEN(TM) X4 CRT-Ds. The X4 line of quadripolar CRT-Ds offers 70% more pacing options to address high capture thresholds and phrenic nerve stimulation effectively, along with the larger battery capacity in the industry. These newly approved devices continue the Boston Scientific history of projected longevity and a six-year CRT-D warranty. The small dimensions of the MINI ICD are up to 20% smaller by volume and up to 24% thinner than competitive devices from other manufacturers. ICDs and CRT-Ds are designed to treat patients suffering from heart failure and/or to provide protection to patients at risk of sudden cardiac death.

Vascular Solutions Announces Preliminary Injunction Against Boston Scientific's Guidezilla Catheter Vacated by Federal Circuit

Vascular Solutions Inc. announced that a three judge panel of the U.S. Court of Appeals for the Federal Circuit vacated the preliminary injunction that was previously issued by the District Court for the District of Minnesota effective January 13, 2014 against Boston Scientific's Guidezilla guide extension catheter. The Court's ruling on the preliminary injunction does not affect the underlying patent litigation, which is currently scheduled to be ready for trial on or after March 2015 in the District Court for the District of Minnesota.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $13.69 USD -0.06

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $113.70 USD -0.49
Olympus Corp ¥3,115 JPY 0.00
Smith & Nephew PLC 884.00 GBp +4.50
St Jude Medical Inc $61.84 USD -1.10
Zimmer Holdings Inc $91.45 USD -0.23
View Industry Companies

Industry Analysis


Industry Average

Valuation BSX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.8x
Price/Cash Flow 63.0x
TEV/Sales 1.9x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at